Medpace Holdings, Inc. $MEDP Stake Increased by Zeno Equity Partners LLP

Key Points

• Zeno Equity Partners LLP increased its stake in Medpace Holdings, Inc. by 2.6%, now owning 62,304 shares valued at approximately $18.98 million, making it the 8th largest position in their portfolio.
• Medpace reported a better-than-expected quarterly earnings with $3.10 EPS, surpassing estimates by $0.10 and achieving a revenue of $603.31 million, a 14.2% increase year-over-year.
• Following recent analyst reviews, Medpace's stock ratings have fluctuated, with a consensus target price now set at $412.73, while two analysts maintain a Buy rating and eleven have a Hold rating.

Zeno Equity Partners LLP increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2.6% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 62,304 shares of the company's stock after purchasing an additional 1,564 shares during the period. Medpace accounts for 6.5% of Zeno Equity Partners LLP's investment portfolio, making the stock its 8th largest position. Zeno Equity Partners LLP owned about 0.22% of Medpace worth $18,983,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after purchasing an additional 102,015 shares in the last quarter. Mawer Investment Management Ltd. purchased a new stake in shares of Medpace in the 1st quarter valued at about $212,131,000. Bessemer Group Inc. raised its holdings in shares of Medpace by 1.1% in the 1st quarter. Bessemer Group Inc. now owns 582,269 shares of the company's stock valued at $177,411,000 after acquiring an additional 6,225 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Medpace by 12.4% in the 1st quarter. AQR Capital Management LLC now owns 539,547 shares of the company's stock valued at $158,470,000 after acquiring an additional 59,361 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Medpace by 36.0% in the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company's stock valued at $102,830,000 after acquiring an additional 89,347 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Trading Up 1.0%

Shares of Medpace stock opened at $492.09 on Tuesday. The firm has a market capitalization of $13.82 billion, a PE ratio of 36.59, a price-to-earnings-growth ratio of 3.06 and a beta of 1.44. The business's 50-day moving average price is $416.25 and its 200-day moving average price is $345.24. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company's revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at $4,654,350. This trade represents a 22.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of the firm's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the transaction, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 over the last quarter. Company insiders own 20.30% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Rothschild & Co Redburn cut Medpace from a "buy" rating to a "neutral" rating and raised their price target for the company from $342.00 to $474.00 in a report on Wednesday, September 3rd. Rothschild Redb cut Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. Deutsche Bank Aktiengesellschaft raised their price target on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Robert W. Baird raised their price target on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of "Reduce" and a consensus target price of $412.73.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.